Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC By Ogkologos - September 17, 2026 56 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a second planned interim analysis of the AEGEAN study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR No Improvement in OS with Adding Palbociclib to Letrozole for the... January 24, 2024 Working to Raise Prostate Cancer Awareness: A Patient Advocate’s Story January 25, 2022 Long-Term Responders with No Evidence of Disease Have Better Survival to... May 16, 2022 A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... February 6, 2023 Load more HOT NEWS Coping with Grief: An Interview with Author Rebecca Munn FDA Approves Updated Drug Labelling Including New Indications and Dosing Regimens... A 27-Year-Old Woman Passed Away. The Note She Wrote The Day... Breast cancer surgery: ‘I’m proud of the tattoos inked across my...
